Latest Regulatory News

BlinkLab Limited has secured independent scientific validation for its smartphone-based autism diagnostic technology through publication in the prestigious journal Autism Research, marking a significant milestone ahead of its FDA regulatory trial.

Island Pharmaceuticals reports ongoing FDA review of its antiviral Galidesivir, with no adverse feedback received as the regulator takes extra time to finalise guidance.

New Frontier Minerals has moved its Mining Lease Application for the Big One Copper Deposit into the technical assessment phase, marking a key step toward near-term development amid a strong copper market.

Renergen Limited and Asp Isotopes Inc. have outlined the process for cash payments to shareholders for fractional entitlements following their share acquisition scheme.

I Synergy Group Limited has announced a planned 5-for-1 consolidation of its ordinary shares and options, pending shareholder approval. The move aims to reduce the number of securities on issue, with trading of consolidated shares set to begin in early February.

Calix Limited has responded to an ASX price query following a notable rise in its share price and trading volume, confirming no undisclosed information and full compliance with listing rules.

Taiton Resources has completed the first tranche of its capital raising, issuing 3.38 million shares to sophisticated investors, with a larger tranche still pending. This move aims to bolster funding for its mineral exploration projects across South Australia and New South Wales.

Next Science Limited’s shares have been suspended from ASX trading due to insufficient ongoing operations following the disposal of its main business. The suspension raises questions about the company’s future direction and compliance with listing rules.

NT Minerals Limited has been suspended from ASX trading due to failure to meet operational requirements, raising questions about its future viability.

Elsight has transitioned from development to production with its new Aura communications platform, delivering initial units to a leading defence contractor and expanding its U.S. presence amid a strong financial turnaround in 2025.

Iron Road has declined to extend Revera Energy’s option to purchase a strategic 24-hectare land parcel at Cape Hardy, marking a significant shift in their green hydrogen project partnership. Two larger land purchase options remain active, with potential buyback rights now triggered.

Neurizon Therapeutics has progressed its ALS treatment NUZ-001 into critical clinical trial phases, even as the FDA declines its Fast Track Designation request pending more data.